ABBV stock icon

AbbVie
ABBV

$168.59
1.72%
 

About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Employees: 50,000

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 13 analysts
0
News positive %
of 70 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

29% more call options, than puts

Call options by funds: $2.84B | Put options by funds: $2.2B

16% more capital invested

Capital invested by funds: $192B [Q4 2023] → $223B (+$31B) [Q1 2024]

9% more funds holding in top 10

Funds holding in top 10: 197 [Q4 2023] → 214 (+17) [Q1 2024]

0% less funds holding

Funds holding: 3,226 [Q4 2023] → 3,222 (-4) [Q1 2024]

0.69% less ownership

Funds ownership: 70.21% [Q4 2023] → 69.52% (-0.69%) [Q1 2024]

2% less first-time investments, than exits

New positions opened: 198 | Existing positions closed: 202

11% less repeat investments, than reductions

Existing positions increased: 1,276 | Existing positions reduced: 1,434

Research analyst outlook

13 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$156
7%
downside
Avg. target
$186
10%
upside
High target
$200
19%
upside

13 analyst ratings

12 positive
92%
neutral
8%
negative
0%
HSBC
Rajesh Kumar
10%upside
$185
Buy
Upgraded
5 Jun 2024
Cantor Fitzgerald
Louise Chen
19%upside
$200
Overweight
Initiated
17 May 2024
Barclays
Carter Gould
11%upside
$187
Overweight
Maintained
29 Apr 2024
BMO Capital
Evan David Seigerman
7%upside
$180
Outperform
Maintained
29 Apr 2024
Barclays
Carter Gould
16%upside
$195
Overweight
Maintained
27 Mar 2024

Financial journalist opinion

Based on 70 articles about ABBV published over the past 30 days